Brief: Ocumension Therapeutics Says Ot-401 (Yutiq) Approved For Real World Study In China
28/12/2020 15:17
Dec 28 (Reuters) - Ocumension Therapeutics 1477.HK :
* OT-401 (YUTIQ) APPROVED FOR REAL WORLD STUDY IN BOAO
LECHENG
INTERNATIONAL MEDICAL TOURISM PILOT ZONE IN CHINA
Source text for Eikon: ID:nHKSccwM53
Further company coverage: 1477.HK
(Reporting by Yamini C S)
((Yamini.CS@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application